Is Sickle Cell Disease Curable? Supportive Care vs Cure

Sickle cell disease is curable, but only by two treatments: a bone marrow transplant or gene therapy. Everything else, from vaccines and antibiotics to transfusion, hydroxyurea and L-glutamine, relieves symptoms and prevents some complications without stopping the sickling that causes them. Supportive care keeps patients alive and improves their days; only a curative treatment halts the silent organ damage that continues underneath.

That distinction ran through the masterclass given by Dr. Arun Singh Danewa, Senior Consultant – Pediatric-Haemato-Oncology & Bone Marrow Transplant (Unit II), Artemis Hospitals, Gurugram, India, in September 2026. This article explains why the disease does so much damage, what good supportive care consists of, where the new drugs have succeeded and failed, and why he urges families who can reach a cure to pursue it. The transplant itself is described step by step in the complete guide to the sickle cell bone marrow transplant process.

What goes wrong in sickle cell disease

Sickle cell disease is caused by a single change in the gene for beta-globin, part of the haemoglobin molecule: one amino acid, glutamic acid, is replaced by valine. This turns normal adult haemoglobin into haemoglobin S, or sickle haemoglobin, and that one substitution is the molecular basis of the entire disease.

Red cells carrying haemoglobin S lose their normal properties. They become stiff and sticky, cling to each other and clog small blood vessels. Every organ depends on blood flow, so any organ can be harmed, and the blockages recur throughout the patient's life. In Dr. Danewa's words, it is not fun to live with sickle cell disease, and only patients and families fully understand the pain.

How sickle cell disease is inherited

Sickle cell disease is inherited recessively. A child of two parents with normal haemoglobin is unaffected. If one parent carries the sickle gene (sickle cell trait, written AS), the children may be carriers but will not have the disease. When both parents are carriers, each pregnancy carries a 25% chance of a child with full sickle cell disease (SS).

Prevention therefore starts with knowing one's carrier status. Dr. Danewa urged that everyone learn their sickle cell status, just as people in thalassaemia-prone regions should know their thalassaemia status, because couples who know they are both carriers can be offered testing in pregnancy. Carrier testing and genetic counselling sit within medical genetics.

Testing the baby before birth

When both partners are known carriers, the fetus can be tested during pregnancy. Chorionic villus sampling, which takes a small sample of placental tissue, can be done from about 11 weeks; amniocentesis, which samples the fluid around the baby, from about 15 weeks. Fetal blood sampling from the umbilical cord (cordocentesis) is possible later, around 18 to 20 weeks, but carries a higher risk of complications. The genetic test shows whether the baby is unaffected, a carrier or affected. Whether termination is then an option depends on the law of the country and on the family's own decision; in India it is legal for a genetic condition of this kind.

A global burden concentrated in Africa and India

Haemoglobin disorders, mainly sickle cell disease and thalassaemia, rank third among congenital conditions in Dr. Danewa's account, after congenital heart disease and neural tube defects. He cited data showing more than 300,000 babies born with haemoglobin disorders every year.

Sickle cell disease is common across Africa and in India. Nigeria carries the largest burden of any country, and several other African countries have high rates. Dr. Danewa noted that the form of the disease seen in India is symptomatically milder than the African variants. India, for its part, is often called the thalassaemia capital of the world, as he pointed out.

Why sickle cell disease is more than anaemia

Sickle cell disease affects the body from head to toe. Dr. Danewa walked through the organs one by one:

• Bones and joints: pain crises, in which blocked vessels make patients feel as if their bones and joints are breaking. Cold weather, stress and infection can trigger them.
• Lungs: acute chest syndrome, which resembles pneumonia, with low oxygen, rapid breathing and an abnormal chest X-ray; patients can end up in intensive care.
• Brain: silent infarcts, or overt strokes that can leave a patient wheelchair-bound for life. Repeated small events cause cognitive decline, which may show up as a child falling behind at school, struggling with mathematics.
• Spleen: repeated blockages destroy the spleen's function within the first years of life (he cited four to six years). The spleen is still there but no longer works, a state called functional asplenia, which leaves the patient vulnerable to encapsulated bacteria such as Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis.
• Kidneys: chronic kidney disease, sometimes progressing to dialysis.
• Hips: avascular necrosis of the femoral head, another common complication, is the death of bone in the ball of the hip joint when its blood supply is cut off. It leaves patients in severe pain, unable to walk and on crutches. Many travel to India for hip or joint replacement for this reason.
• Eyes and heart: bleeding inside the eye and a weakened heart.
• Reproductive organs: priapism, a painful, prolonged erection caused by sickling, can lead to lifelong erectile dysfunction if it lasts beyond about four hours; repeated sickling in the ovaries can cause infertility in women.

Can sickle cell carriers have a crisis?

Carriers of sickle cell trait usually have no symptoms, but extreme conditions can provoke them. Dr. Danewa cited high altitude without acclimatisation, severe cold (which constricts blood vessels), stress and infection. Symptoms in carriers are mild to moderate and much less severe than in sickle cell disease.

What supportive care for sickle cell disease includes

Supportive care is lifelong and has five parts in Dr. Danewa's practice.

1. Vaccination against pneumococcus, Haemophilus influenzae and meningococcus, because of the non-functioning spleen.
2. Pain management, which starts with paracetamol and escalates to tramadol and then morphine. Repeated hospital admissions for pain crises are common.
3. Education about the triggers of a pain crisis, such as changes in weather and infection.
4. Transfusion. Once a patient has had a stroke, the recommendation he cited is to keep haemoglobin above 9 g/dL with repeated transfusion to dilute the proportion of sickle cells and reduce the risk of another stroke. Standard chronic transfusion programmes also aim to keep haemoglobin S below about 30%. In children, transcranial Doppler ultrasound, which measures blood flow velocity in the brain's arteries, identifies those at high risk of a first stroke; when the velocity crosses the established threshold, chronic transfusion is started.
5. Disease-modifying drugs, chiefly hydroxyurea and L-glutamine.

Hydroxyurea and L-glutamine

Hydroxyurea is the oldest disease-modifying drug for sickle cell disease. It was approved by the US Food and Drug Administration for adults in 1998 and later for children from two years of age. Dr. Danewa said it can now be used from six months of age, and US guidance (NHLBI) recommends offering it from nine months. His view is unambiguous: hydroxyurea should be on the medicine chart of every single patient, with the dose set by weight.

L-glutamine is the second proven drug. Dr. Danewa cited a 25% reduction in pain crises. For patients who cannot afford a cure, he recommends both drugs for everyone, alongside vaccination and education, while further drugs continue in trials.

Two drugs that failed

Not every new drug has delivered. Voxelotor, marketed by Pfizer, showed early promise but was withdrawn from the market because of safety concerns. Crizanlizumab, another promising agent, failed to show benefit over placebo in its confirmatory phase 3 trial, and its European marketing authorisation was revoked in 2023. Dr. Danewa cited both as drugs that looked promising but failed to show their expected effect in sickle cell disease.

Why better drugs will not replace a cure

Disease-modifying drugs reduce symptoms and their severity, but they do not touch the primary pathology, the sickling itself. The silent, chronic complications continue inside the body even when the pain is controlled. Asked whether better drugs might one day make transplant unnecessary, Dr. Danewa said no: the underlying disease can be corrected only by bone marrow transplant or gene therapy. His guidance to referring doctors was direct. If curative therapy is available and affordable, pursue it; if not, give the best possible supportive care for quality of life.

The lifetime cost of supportive care

Supportive care is not cheap; it is merely paid in instalments. Dr. Danewa estimates that over a lifetime, the cost of hospital admissions and drugs adds up to roughly the cost of a bone marrow transplant. The difference is that a transplant requires the whole sum at once, in a short time, which is what makes it feel unaffordable. He described adults in their mid-thirties who tell him they will accept any transplant risk because they are fed up with the disease. Transplant costs at his centre are set out in the complete guide.

Is sickle cell disease curable? The two curative options

Yes: sickle cell disease can be cured by a bone marrow transplant or by gene therapy, and the two cures work in different ways. A bone marrow transplant replaces the patient's blood-forming system with a donor's; gene therapy corrects the patient's own.

Bone marrow transplant

Bone marrow transplant is the established cure, available today and at a fraction of Western cost in India. It requires a donor, and its main risks, graft-versus-host disease and graft failure, come from introducing another person's cells. How donors are matched and prepared is covered in the article on HLA matching and conditioning, and how the graft is monitored afterwards in the article on engraftment and chimerism.

Gene therapy

Because sickle cell disease is caused by a single gene, scientists have tried for decades to correct that gene, and the problem has now been cracked. In December 2023 the US Food and Drug Administration approved the first two gene therapies for sickle cell disease, initially for patients aged 12 and over: exagamglogene autotemcel (Casgevy), which uses CRISPR gene editing, and lovotibeglogene autotemcel, which uses a lentiviral vector to add a working gene. The methods differ, but both use the patient's own (autologous) stem cells, so there is no donor search and no graft-versus-host disease.

The barrier is cost. Casgevy launched in the United States at about USD 2.2 million, a price that developing countries in Africa and South Asia cannot meet. In India, the CSIR Institute of Genomics and Integrative Biology (IGIB) is developing an indigenous gene therapy, still in trials, which Dr. Danewa expects to cost around 30 to 40 lakh rupees once approved. Until then, bone marrow transplant remains the affordable cure.

Choosing between supportive care and cure

For a family weighing the options, the logic of Dr. Danewa's lecture reduces to three questions. Is a suitable donor available? Has the disease already damaged the organs? Can the family reach and fund a transplant now? Where the answers allow, early transplant offers a cure with medication stopping after about a year. Where they do not, hydroxyurea, L-glutamine, vaccination, transfusion where indicated and education about triggers give the best quality of life the disease allows.

Questions from the session on inheritance after cure and on carrier symptoms are recorded on the Live Discussion page. For a detailed treatment of crisis management and stroke prevention, see Dr. Divya Doval's sickle cell guide.